Anbio Biotechnology (NNNN): Total Assets
$30.24M
As of 2025-12-31
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.24M | +59.8% | 2026-04-07, Balance as of period end |
| 2024-12-31 | $18.92M | +19.7% | 2026-04-07, Balance as of period end |
| 2023-12-31 | $15.81M | n/a | 2025-04-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Anbio Biotechnology (NNNN) | 2025-12-31 | $30.24M | +59.8% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $5.46M | -0.6% |
| Biomerica Inc (BMRA) | 2026-05-31 | $6.76M | +13.7% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $25.76M | -26.6% |
| Immucell Corp (ICCC) | 2025-12-31 | $42.53M | -5.7% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $103.58M | -12.8% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $6.90M | -26.6% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $582.98M | -26.4% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $842.13M | -29.3% |
Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗